Direct thrombin inhibitors in cardiovascular disease

Coronary Artery Disease

Volumn 8, Issue 2, 1997, Pages 105-111

  Catella Lawson, Francesca ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Direct thrombin inhibitors

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; HEPARIN LYASE; HIRUDIN; HIRULOG; THROMBIN; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4;

ANTICOAGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DILATATION; DOSE RESPONSE; HUMAN; META ANALYSIS; METHODOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0030995712     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199702000-00007     Document Type: Review

References (34)

1. Hirsh J, Dalen J, Deykin D, Poller L: Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1992, 4:337S-351S.
2. Antman E: Hirudin in acute myocardial infarction safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994, 90:1624-1630.
3. GUSTO Iia Investigators: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994, 90:1631-1637
4. Neuhaus K, Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W, et al.: Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation 1994, 90:1638-1642.
5. Antman EM, for the TIMI 9B Investigators: Hirudin in acute myocardial infarction. thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996, 94:911-921.
6. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIB Investigators: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996, 335:775-782.
7. Serruys P, Herman J-P, Simon R, Rutsch W, Bode C, Laarman G-J, et al.: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995, 333:764-769.
8. Bittl J, Strony J, Brinker J, Ahmed W, Meckel C, Chaitman B, et al.: Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995, 333:764-769.
9. Fitzgerald D, Murphy N: Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Coronary Artery Dis 1996, 7:455-458.
10. Cannon C, McCabe C, Henry T, Schweiger M, Gibson R, Mueller H, et al.: A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994, 23:993-1003.
11. Lee L: initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial. Am J Cardiol 1995, 75:7-13.
12. Topol E, Fuster V, Harrington R, Califf R, Kleiman N, Kereiakes D, et al.: Recombinant hirudin for unstable angina pectoris. Circulation 1994, 89:1557-1566.
13. Marbet GA, Verstraete M, Kienast J, Graf P, Hoet B, Tsakiris DA et al.: Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiorasc Pharm 1993, 22:364-372.
14. Zoldhelyi P, Webster W, Fuster V, Grill D, Gaspar D, Edwards S, et al.: Recombinant hirudin in patients with chronic stable coronary artery disease. Circulation 1993, 88:2015-2022.
15. Dougherty KG, Gaos CM, Bush HS, Leachman R, Ferguson JJ, et al.: Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovas Diagn 1992, 26:260-263.
16. Varah N, Smith J, Baugh RF: Heparin monitoring in the coronary care unit after percutaneous transluminal coronary angioplasty. Heart Lung 1990, 19:265-270.
17. Lidon R-M, Theroux P, Lesperance J, Adelman B, Bonan R, Duval D, et al.: A pilot early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994, 89:1567-1572.
18. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V: Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989, 79:657-665.
19. Molhoek GP, Laarman GJ, Lok DJ, Luz M, Kingma JH, van den Bos AA, et al.: Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK). Eur Heart J 1995, 16S: D33-D37.
20. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators: Comparison of hirudin with heparin and warfarin with control for unstable angina and non Q wave MI in a randomized controlled trial. Circulation 1995, 92:1982A
21. tm, a direct thrombin inhibitor, in humans. Thromb Hemost 1993, 69:157-163.
22. Cannon C, Maraganore J, Loscalzo J, McAllister A, Eddings K, George D, et al.: Anticoagulant effects of Hirulog,* a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 1993, 71:778-782.
23. Nguyen ND, Ghaddar H, Stinson V, Chambless LE, WuKK: ARIC hemostasis study -IV. Intraindividual variability and reliability of hemostatic factors. The Atherosclerotic Risk in Communities (ARIC). Thromb Haemost 1995, 73:256-260.
24. Lidon R-M, Theroux P, Juneau M, Adelman B, Maraganore J: Initial experience with a direct antithrombin, Hirulog, in unstable angina. Circulation 1993, 88:1495-1501.
25. Fuchs J, Cannon C: Hirulog in the treatment of unstable angina results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation 92:727-733.
26. Theroux P, Ouimet H, McCans J, Latour J-G, Joly P, Levy G, et al.: Aspirin, heparin, or both to treat acute unstable angina. N Eng J Med 1988, 319:1105-1111.
27. Sharma G, Lapsley D, Vita J, Sharma S, Coccio E, Adelman B, Loscalzo J, et al.: Usefulness and tolerability of Hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am J Cardiol 1993, 72:1357-1360.
28. Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R: Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995, 91:2132-2139.
29. Topol E, Bonan R, Jewitt D, Sigwart U, Kakkar V, Rothman M, et al.: Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993, 87:1622-1629.
30. McGarry TF, Gottlieb RS, Morganroth J, Zelenkofske SL, Kasparian H, Duca PR, et al.: The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J 1992, 123:1445-1451.
31. Carteaux JP, Gast A, Tschopp T, Roux S: Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or RO 46-6240 in experimental arterial thrombosis. Circulation 1995, 91:1568-1574
32. van den Bos A, Deckers J, Heyndrickx R, Laarman G-J, Suryapranata H, Zijlstra F, et al.: Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993, 88:2058-2066.
33. Hafner G, Rupprecht HJ, Luz M, Terrs W, Schindel F, Friesen HJ, et al.: Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris. Eur Heart J 1996, 17:1207-1215.
34. Calla DD, Hoppensteadt D, Fareed J: Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Semin Thromb Hemost 1995, 21:177-183.